SSC
IPSC icon

Spruce Street Capital’s Century Therapeutics IPSC Stock Holding History

Spruce Street Capital’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.94M Hold
4,059,054
– – 1.95% 16
2026
Q1 		$9.17M Buy
4,059,054
+2,637,522
+186% +$5.55M 2.21% 17
2025
Q4 		$1.41M Buy
+1,421,532
New +$867K 0.47% 26

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Spruce Street Capital's IPSC Position: Q2 2026 in Review

Spruce Street Capital held its Century Therapeutics (IPSC) position steady in Q2 2026 at 4,059,054 shares worth $9.94M. The position accounts for 1.95% of the portfolio, ranked #16.

Spruce Street Capital first reported a position in IPSC in Q4 2025 and has held it in 3 quarters since. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • Spruce Street Capital held 4,059,054 shares of Century Therapeutics worth $9.94M as of Q2 2026.
  • Spruce Street Capital left its Century Therapeutics share count unchanged in Q2 2026.
  • Century Therapeutics made up 1.95% of Spruce Street Capital's portfolio in Q2 2026, its #16 holding.
  • Spruce Street Capital first reported a position in Century Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Spruce Street Capital's 13F filing for Q2 2026, filed 13 Aug 2026.